The leading players in the Europe platelet rich plasma (PRP) market are EmCyte Corporation, Arthrex, Inc., AdiStem Ltd, Medira Ltd., and Biomet, Inc. Transparency Market Research observed that Anthex Inc. led the market in 2013 with its wide product portfolio that offers a variety of solutions for orthopedic disorders. “Companies must focus on developing impactful distribution and marketing strategies to target several small nations of Europe to retain their dominance in the near future,” states the lead author of this research report.
According to the research report, the Europe platelet rich plasma market is expected to be worth US$ 87.2 mn by 2022 from US$42.1 mn in 2013. During the forecast years of 2014 and 2022, the overall market is anticipated to rise at a CAGR of 8.30%. The key countries operating in the market are Greece, Spain, Italy, France, Germany, and the U.K. Analysts predict that the leukocyte-platelet rich fibrin (L-PRF) segment is expected to witness a significant growth rate in the coming years as it offers advantages such as reduced recovery period and cost-effectiveness.
This 89 page report gives readers a comprehensive overview of the Europe platelet rich plasma market. Browse through 8 data tables and 28 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/europe-platelet-rich-plasma-market.html
Market Thrives with Product Innovation
The market is also likely to be driven by the ongoing technological advancements in the production of platelet rich plasma. The advancements such as improved PRP preparation time has revolutionized the overall market. Product innovation is expected to result in a significant demand for platelet rich plasma in the near future across Europe. The growing advantages of using PRP products and devices is also likely to fuel the market growth during the forecast period. The innovation of PRP products and devices to treat male sexual disorders, vascular venous disorders, eye disorders, burn care, and lipofilling are expected to open up new avenues for growth for the Europe platelet rich plasma.
The high prevalence of chronic conditions is anticipated to be the primary growth driver for the Europe platelet rich plasma market in the near future. The high prevalence of chronic conditions related to orthopedics is expected to favor the growth of the global market. The increasing participation in sporting activities has led to a rise in orthopedic injuries in recent years, which has had a positive impact on the growth of the global market. The growing number of patients suffering from osteoporosis are also augmenting the demand for various types of platelet rich plasma products and devices as they are highly susceptible to fractures.
Controversy Stating PRP being Placebo Challenges Global Market
The aforementioned market drivers are being considerably challenged. The predominant hurdle for the Europe platelet rich plasma market is the exceptionally high cost of PRP products and devices. This issue is further complicated by the poor reimbursement policies. The market is also being stymied by the possibilities of failure of therapy being offered to patients and the chances of disease transfer. Additionally, the controversy surrounding PRP therapy technique has persistently inclined towards the theory that it is a mere placebo. All of these factors are expected to tug the market’s growth in the opposite direction.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving Europe platelet rich plasma market during 2014 - 2022: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4761
The review is based on Transparency Market Research’s report, titled “Platelet Rich Plasma Market - Europe Industry Analysis, Size, Share, Growth, Trends & Forecast 2014 -2022.”
According to the research report, the Europe platelet rich plasma market is expected to be worth US$ 87.2 mn by 2022 from US$42.1 mn in 2013. During the forecast years of 2014 and 2022, the overall market is anticipated to rise at a CAGR of 8.30%. The key countries operating in the market are Greece, Spain, Italy, France, Germany, and the U.K. Analysts predict that the leukocyte-platelet rich fibrin (L-PRF) segment is expected to witness a significant growth rate in the coming years as it offers advantages such as reduced recovery period and cost-effectiveness.
This 89 page report gives readers a comprehensive overview of the Europe platelet rich plasma market. Browse through 8 data tables and 28 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/europe-platelet-rich-plasma-market.html
Market Thrives with Product Innovation
The market is also likely to be driven by the ongoing technological advancements in the production of platelet rich plasma. The advancements such as improved PRP preparation time has revolutionized the overall market. Product innovation is expected to result in a significant demand for platelet rich plasma in the near future across Europe. The growing advantages of using PRP products and devices is also likely to fuel the market growth during the forecast period. The innovation of PRP products and devices to treat male sexual disorders, vascular venous disorders, eye disorders, burn care, and lipofilling are expected to open up new avenues for growth for the Europe platelet rich plasma.
The high prevalence of chronic conditions is anticipated to be the primary growth driver for the Europe platelet rich plasma market in the near future. The high prevalence of chronic conditions related to orthopedics is expected to favor the growth of the global market. The increasing participation in sporting activities has led to a rise in orthopedic injuries in recent years, which has had a positive impact on the growth of the global market. The growing number of patients suffering from osteoporosis are also augmenting the demand for various types of platelet rich plasma products and devices as they are highly susceptible to fractures.
Controversy Stating PRP being Placebo Challenges Global Market
The aforementioned market drivers are being considerably challenged. The predominant hurdle for the Europe platelet rich plasma market is the exceptionally high cost of PRP products and devices. This issue is further complicated by the poor reimbursement policies. The market is also being stymied by the possibilities of failure of therapy being offered to patients and the chances of disease transfer. Additionally, the controversy surrounding PRP therapy technique has persistently inclined towards the theory that it is a mere placebo. All of these factors are expected to tug the market’s growth in the opposite direction.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving Europe platelet rich plasma market during 2014 - 2022: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4761
The review is based on Transparency Market Research’s report, titled “Platelet Rich Plasma Market - Europe Industry Analysis, Size, Share, Growth, Trends & Forecast 2014 -2022.”
No comments:
Post a Comment